Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2216573 | 0.73 | RAPGEF4 (0.34) | MAPTKMO | |
| SCHEMBL419343 | 0.69 | — | — | |
| SCHEMBL30337397 | 0.69 | — | — | |
| SCHEMBL4049600 | 0.68 | MEN1 (0.38) | NISCHKMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL60954 | 0.67 | — | — | |
| SCHEMBL30527 | 0.67 | — | — | |
| SCHEMBL12377626 | 0.67 | NISCH (0.52) | HDAC1HDAC6ACHENISCHALDH1A1 | |
| SCHEMBL29367748 | 0.67 | — | — | |
| SCHEMBL30167752 | 0.67 | — | — | |
| P-Xylene SCHEMBL28885091 | 0.65 | ACHE (0.48) | HDAC1HDAC6ACHENISCHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1709046-A1 | P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073232-A1 | P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | HDAC1 872/4885HDAC6 1773/4885ACHE 1563/4885 |
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | HDAC1 413/4885HDAC6 515/4885ACHE 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.